news
Fostamatinib reduces COVID-19 risks by 50 percent in Phase II study
Fostamatinib significantly reduced serious adverse effects and risk of death in hospitalised COVID-19 patients, shows Phase II study.
List view / Grid view
National Heart Lung and Blood Institute (NHLBI)
news
Blood thinners reduce need for organ support in COVID-19 patients
Clinical trial shows that treating moderately ill COVID-19 patients with a full-dose blood thinner reduced their need for organ support.
news
NIH halts COVID-19 convalescent plasma trial
The trial evaluating COVID-19 convalescent plasma as a treatment for COVID-19 patients with mild to moderate symptoms was stopped due to ineffectiveness.
news
NIH launches antithrombotics trials in COVID-19 patients
The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.
news
FDA approves first generic albuterol sulfate metered dose inhaler
The generic Proventil HFA (albuterol sulfate) metered dose inhaler has been approved for the prevention of bronchospasm in patients four years of age and older.
news
Psoriasis treatment linked to improvement in heart disease
Treatments for psoriasis could help prevent heart disease in patients with the skin condition, with patients having an 8 percent reduction in their risk...
news
New study offers insights on genetic indicators of COPD risk
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who are particularly at risk for COPD...
